Diabetic Peripheral Neuropathic Pain

The Diabetic Peripheral Neuropathic Pain pipeline: 16 tracked drugs, 4 approved for this indication.

4 approved / phase 43 Phase 37 Phase 21 Phase 11 preclinical / unstaged

Compare the share prices of listed companies in Diabetic Peripheral Neuropathic Pain →

Total attributable cost

$101.0B

$16,588/patient

Drug spend

Not yet sourced

How this is calculated ↗

All severities · US

The Diabetic Peripheral Neuropathic Pain pipeline

Key trial results for every approved and late-stage drug: Diabetic Peripheral Neuropathic Pain results by drug.

← all assets